117 related articles for article (PubMed ID: 23930696)
1. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Bakhous A; Zhu H; Waheed S
Br J Haematol; 2013 Nov; 163(3):293. PubMed ID: 23930696
[No Abstract] [Full Text] [Related]
2. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Terpos E; Christoulas D; Kokkoris P; Anargyrou K; Gavriatopoulou M; Migkou M; Tsionos K; Dimopoulos MA
Ann Oncol; 2010 Jul; 21(7):1561-1562. PubMed ID: 20497962
[No Abstract] [Full Text] [Related]
3. Hyperammonemic encephalopathy in multiple myeloma.
Jones FM; Bokhari SW
Ann Hematol; 2014 Aug; 93(8):1431-2. PubMed ID: 24292538
[No Abstract] [Full Text] [Related]
4. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
5. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.
Banwait R; O'Regan K; Campigotto F; Harris B; Yarar D; Bagshaw M; Leleu X; Leduc R; Ramaiya N; Weller E; Ghobrial IM
Am J Hematol; 2011 Jul; 86(7):567-72. PubMed ID: 21681781
[TBL] [Abstract][Full Text] [Related]
6. [Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen].
Szturz P; Jakubcová R; Adam Z; Klincová M; Krejcí M; Pour L; Zahradová L; Hájek R; Mayer J
Klin Onkol; 2011; 24(3):216-20. PubMed ID: 21717791
[TBL] [Abstract][Full Text] [Related]
7. Current therapeutic strategy for multiple myeloma.
Suzuki K
Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Nizeica V; Collet P; Marotte H
Ann Hematol; 2013 Aug; 92(8):1135-6. PubMed ID: 23370597
[No Abstract] [Full Text] [Related]
9. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
11. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
12. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
[TBL] [Abstract][Full Text] [Related]
13. Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.
Morita T; Ugai T; Tanimoto T; Matsue K
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24671324
[TBL] [Abstract][Full Text] [Related]
14. Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Bianchi G; Richardson PG; Anderson KC
J Clin Oncol; 2014 Jul; 32(20):2125-32. PubMed ID: 24888801
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment for plasma cell leukemia].
Miwa A
Nihon Rinsho; 2012 Apr; 70 Suppl 2():628-41. PubMed ID: 23134023
[No Abstract] [Full Text] [Related]
16. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
Leblebjian H; Noonan K; Paba-Prada C; Treon SP; Castillo JJ; Ghobrial IM
Am J Hematol; 2015 Jun; 90(6):E122-3. PubMed ID: 25703132
[No Abstract] [Full Text] [Related]
18. Durable remission of mantle cell lymphoma relapsing a third time after allogeneic hematopoietic stem cell transplantation treated with rituximab, bortezomib, donor lymphocytes, and pegylated interferon.
Vo P; Jaffe ES; Cook L; Ramos C; Childs R
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e1-5. PubMed ID: 23994440
[No Abstract] [Full Text] [Related]
19. Cutaneous macroglobulinosis treated with bortezomib and rituximab.
Marchand T; Tas P; Houot R; Dauriac C; Lamy T; Cahu X
Eur J Haematol; 2011 Jul; 87(1):98. PubMed ID: 21418108
[No Abstract] [Full Text] [Related]
20. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
